Total Payments
$33,488
2024 Payments
$5,508
Companies
43
Transactions
174
Medicare Patients
18,072
Medicare Billing
$7.1M
Payment Breakdown by Category
Consulting$20,923 (62.5%)
Other$6,810 (20.3%)
Food & Beverage$3,270 (9.8%)
Travel$2,198 (6.6%)
Education$267.47 (0.8%)
Gifts$20.10 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $20,923 | 18 | 62.5% |
| Honoraria | $5,250 | 5 | 15.7% |
| Food and Beverage | $3,270 | 137 | 9.8% |
| Travel and Lodging | $2,198 | 5 | 6.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,560 | 1 | 4.7% |
| Education | $267.47 | 7 | 0.8% |
| Gift | $20.10 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| OnMark, Inc. | $18,437 | 24 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,915 | 11 | $0 (2023) |
| G1 Therapeutics, Inc. | $3,500 | 2 | $0 (2022) |
| US Oncology Corporate, Inc. | $2,543 | 6 | $0 (2023) |
| Genmab U.S., Inc. | $1,569 | 2 | $0 (2023) |
| McKesson Specialty Care Distribution, LLC | $1,128 | 2 | $0 (2020) |
| Millennium Pharmaceuticals, Inc. | $506.15 | 3 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $221.42 | 11 | $0 (2022) |
| Alexion Pharmaceuticals, Inc. | $169.67 | 3 | $0 (2019) |
| PFIZER INC. | $150.74 | 26 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $5,508 | 9 | OnMark, Inc. ($5,495) |
| 2023 | $13,419 | 24 | OnMark, Inc. ($10,141) |
| 2022 | $5,905 | 20 | G1 Therapeutics, Inc. ($3,500) |
| 2021 | $1,933 | 27 | US Oncology Corporate, Inc. ($900.00) |
| 2020 | $4,157 | 26 | AstraZeneca Pharmaceuticals LP ($2,876) |
| 2019 | $818.55 | 45 | Alexion Pharmaceuticals, Inc. ($169.67) |
| 2018 | $1,241 | 20 | AstraZeneca Pharmaceuticals LP ($984.06) |
| 2017 | $506.15 | 3 | Millennium Pharmaceuticals, Inc. ($506.15) |
All Payment Transactions
174 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/15/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 09/18/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| 09/13/2024 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $24.91 | General |
| 08/05/2024 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $62.50 | General |
| 06/06/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 05/13/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 02/15/2024 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 01/24/2024 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $157.88 | General |
| 01/18/2024 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Biosimilars | ||||||
| 12/12/2023 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 12/05/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,560.00 | General |
| Category: Oncology | ||||||
| 11/17/2023 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $350.00 | General |
| 10/19/2023 | US Oncology Corporate, Inc. | — | Food and Beverage | Cash or cash equivalent | $632.27 | General |
| 10/19/2023 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $501.84 | General |
| 10/19/2023 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $433.57 | General |
| 10/19/2023 | US Oncology Corporate, Inc. | — | Travel and Lodging | Cash or cash equivalent | $55.47 | General |
| 10/19/2023 | US Oncology Corporate, Inc. | — | Gift | Cash or cash equivalent | $20.10 | General |
| 09/07/2023 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $262.50 | General |
| 08/04/2023 | OnMark, Inc. | — | Consulting Fee | Cash or cash equivalent | $7,000.00 | General |
| 08/02/2023 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $44.46 | General |
| 08/02/2023 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $21.27 | General |
| 08/01/2023 | OnMark, Inc. | — | Travel and Lodging | Cash or cash equivalent | $709.62 | General |
| 08/01/2023 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $387.03 | General |
| 07/31/2023 | OnMark, Inc. | — | Food and Beverage | Cash or cash equivalent | $141.53 | General |
| 07/28/2023 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $9.41 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 71 | 4,246 | 114,131 | $3.7M | $1.7M |
| 2022 | 69 | 3,953 | 108,040 | $3.6M | $1.7M |
| 2021 | 75 | 4,762 | 108,073 | $3.4M | $1.7M |
| 2020 | 80 | 5,111 | 165,961 | $4.0M | $2.0M |
Total Patients
18,072
Total Services
496,205
Medicare Billing
$7.1M
Procedure Codes
295
All Medicare Procedures & Services
295 procedure records from CMS Medicare Utilization — Page 1 of 12
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 31 | 13,602 | $828,800 | $486,243 | 58.7% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 21 | 7,020 | $444,780 | $259,125 | 58.3% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 20 | 10,940 | $439,240 | $258,944 | 59.0% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 58 | 6,960 | $230,640 | $128,625 | 55.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 358 | 796 | $220,881 | $106,388 | 48.2% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 50 | 25,890 | $269,225 | $60,901 | 22.6% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 13 | 5,100 | $107,100 | $52,513 | 49.0% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 28 | 468 | $196,104 | $36,502 | 18.6% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 20 | 2,100 | $75,600 | $33,731 | 44.6% |
| Q5108 | Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg | Office | 2023 | 18 | 336 | $154,224 | $33,477 | 21.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 180 | 316 | $76,282 | $31,053 | 40.7% |
| Q5118 | Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | Office | 2023 | 11 | 1,070 | $83,460 | $24,798 | 29.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 185 | 259 | $51,391 | $23,991 | 46.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 147 | 196 | $25,713 | $12,761 | 49.6% |
| J9041 | Injection, bortezomib, 0.1 mg | Office | 2023 | 19 | 2,660 | $77,910 | $11,339 | 14.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 379 | 1,363 | $11,873 | $10,846 | 91.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 74 | 80 | $24,466 | $10,713 | 43.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 358 | 1,255 | $16,492 | $9,531 | 57.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 128 | 422 | $21,905 | $9,300 | 42.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 269 | 862 | $15,378 | $8,922 | 58.0% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 43 | 137 | $16,570 | $7,510 | 45.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 14 | 56 | $33,376 | $7,410 | 22.2% |
| J9395 | Injection, fulvestrant, 25 mg | Office | 2023 | 19 | 760 | $83,600 | $6,304 | 7.5% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 66 | 112 | $14,288 | $5,466 | 38.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 29 | 29 | $9,362 | $4,765 | 50.9% |
About Dr. Joseph Kannarkatt, M.D
Dr. Joseph Kannarkatt, M.D is a Hematology & Oncology healthcare provider based in York, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/26/2011. The National Provider Identifier (NPI) number assigned to this provider is 1124311956.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Kannarkatt, M.D has received a total of $33,488 in payments from pharmaceutical and medical device companies, with $5,508 received in 2024. These payments were reported across 174 transactions from 43 companies. The most common payment nature is "Consulting Fee" ($20,923).
As a Medicare-enrolled provider, Kannarkatt has provided services to 18,072 Medicare beneficiaries, totaling 496,205 services with total Medicare billing of $7.1M. Data is available for 4 years (2020–2023), covering 295 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location York, PA
- Active Since 05/26/2011
- Last Updated 03/17/2018
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1124311956
Products in Payments
- COSELA (Drug) $3,500
- Epkinly (Drug) $1,569
- CALQUENCE (Drug) $941.41
- OPDIVO (Biological) $164.60
- Soliris (Drug) $150.00
- Avastin (Biological) $96.47
- VELCADE (Drug) $88.45
- LYNPARZA (Drug) $85.08
- VENCLEXTA (Drug) $77.00
- XTANDI (Drug) $75.37
- Stivarga (Drug) $73.29
- Nerlynx (Drug) $68.83
- XPOVIO (Drug) $64.03
- OXBRYTA (Drug) $56.61
- TAGRISSO (Drug) $54.06
- ERLEADA (Drug) $52.67
- Nubeqa (Drug) $42.22
- IBRANCE (Drug) $40.10
- XARELTO (Drug) $38.06
- IMBRUVICA (Drug) $37.73
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in York
Dr. Daniel Efiom-Ekaha, Md, MD
Hematology & Oncology — Payments: $346,462
Hematology & Oncology $346,462
Dr. Dan Sotirescu, M.d, M.D
Hematology & Oncology — Payments: $149,275
Hematology & Oncology $149,275
Chanh Huynh, Md, MD
Hematology & Oncology — Payments: $90,450
Hematology & Oncology $90,450
Joyce Huang, Md Phd, MD PHD
Hematology & Oncology — Payments: $28,862
Hematology & Oncology $28,862
Kimberly Schlesinger, M.d, M.D
Hematology & Oncology — Payments: $5,009
Hematology & Oncology $5,009
Dr. Annie Kannarkatt, M.d, M.D
Hematology & Oncology — Payments: $1,940
Hematology & Oncology $1,940